Editorial reviews. Affiliate fees from some providers don't affect rankings. Disclosure

No advertiser influenceAffiliate fees disclosedReviewed by board-certified clinicians

For Journalists · Researchers · Industry Analysts

Hormonal Health Portal Press Kit

Independent reviewer of US telehealth providers for women's hormonal health — menopause, HRT, PCOS, GLP-1, and adjacent endocrine conditions. Resources below are free to use for press.

Quick contact

Press inquiries / interviews: hello@hormonalhealthportal.com
Editorial / corrections: editorial@hormonalhealthportal.com
Response SLA: within 1 business day for press requests

We respond best to specific topic + deadline + outlet questions. Open-ended inquiries are routed but may take longer.

Fact sheet

Site launch
2026
Providers reviewed
50+
Conditions covered
11 (menopause, HRT, PCOS, GLP-1, fertility, thyroid, sexual wellness, hormonal acne, mental health, weight loss, contraception)
Medical reviewers
Board-certified OB/GYNs, NAMS-CMP clinicians, endocrinologists — all with public credentials
Editorial methodology
8-axis scoring rubric (clinical infrastructure, pricing transparency, patient satisfaction, and more) — publicly documented at /methodology
Verification cadence
Quarterly per-brand review against FDA Warning Letter database + state telehealth registries
Revenue model
Affiliate commissions from some providers · FTC 16 CFR Part 255 compliant disclosure · scoring independent from affiliate status
Operating entity
See /legal for full disclosure

Citable resources

Linkable pages with structured methodology + sourced claims. All include canonical URL for citation.

Methodology page →

8-axis editorial scoring rubric with weight breakdown, automatic disqualifiers, and conflict-of-interest policy. Includes worked example with 3 brand scores.

Transparency ranking →

Brands ranked by 5 transparency signals: published outcomes, pricing disclosure, insurance navigation, and editorial-score threshold.

Drug monographs →

In-depth drug profiles drawn from FDA prescribing information and peer-reviewed clinical literature. Side effects with incidence rates, dosing, pregnancy.

Editorial guidelines →

Sourcing standards, medical-reviewer sign-off, conflict-of-interest policy, and AI usage policy.

Corrections policy →

How factual errors are reported, our 48-hour acknowledgment SLA, and public correction-log policy.

Affiliate disclosure →

Full disclosure of how affiliate relationships work, FTC 16 CFR Part 255 compliance, and confirmation that affiliate status does NOT affect scoring.

Expert sources / interview topics

Our editorial team + medical reviewer network can speak to the following topics. credentialed clinicians available for on-record commentary.

  • Menopause + perimenopause care
  • Hormone replacement therapy (HRT) trends + safety
  • GLP-1 receptor agonists (semaglutide, tirzepatide, compounded formulations)
  • PCOS phenotypes + treatment approaches
  • Telehealth regulatory + state-licensing landscape
  • Women's health affordability + insurance coverage gaps
  • FDA warning letters + compounded-medication regulation
  • Patient outcome measurement in telehealth

Brand assets

Site name: Hormonal Health Portal
Tagline: “Editorial reviews of women's hormonal telehealth”
Operating entity: Hormonal Health Portal Editorial
Jurisdiction: Monaco

High-res logos / wordmarks: request via hello@hormonalhealthportal.com — we'll share Figma file + PNG/SVG exports.

Citation guidance

When citing our content, please use the canonical URL from the page itself (visible in each page header). Suggested citation format:

Hormonal Health PortalEditorial Team. (2026). “Title of Article” [Online]. Available: https://womens.84-247-163-89.nip.io/path-to-article (Accessed: [date]).

For named medical-reviewer attribution, see the byline under each article H1. All reviewers have public NPI numbers + linked profiles at /medical-advisors.

Related resources